YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Teresa Chen, Master
Beijing Inno Medicine Co., Ltd.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China
- Peking University First Hospital
Beijing, Beijing Municipality, China
- Renmin Hospital of Wuhan University
Wuhan, Hubei, China
- Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
- First Hospital of Jilin University
Changchun, Jilin, China
- Renji Hospital Shanghai Jiaotong Unv. School of Medicine
Shanghai, Shanghai Municipality, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 Oct 2023
- Primary completion
- 27 Apr 2025
- Completion
- 27 Apr 2025
- Last update posted
- 30 Apr 2025
- Registered enrollment
- 144
- Registry id
- NCT06048588
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.